Connor Iapoce

Matthew J. Budoff, MD describes bridging the gap between atherosclerosis and osteoporosis through advanced Imaging techniques.

Lowering serum urate level to less than 6 mg/dL was not linked to an elevated risk of severe or end-stage kidney disease progression in patients with gout.

Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.

Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.

Patients with gout demonstrated higher rates of multiple medical and surgical complications than non-gout patients after primary THA.

Levels of obesity indicators, including body mass index and waist circumference, were notably higher in patients with gout compared to those without gout.

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Urate-lowering therapy was strongly associated with successful treat-to-target benchmarks in gout, including serum uric acid levels, but adherence remained low.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

People with diabetes exhibit significantly greater odds of developing carpal tunnel syndrome compared with non-diabetic individuals.

Monosodium urate deposits significantly increased the risk of major cardiovascular events in patients with gout and hyperuricemia.

An observational study in the UK investigated the risk of adverse events related to colchicine prophylaxis after receiving allopurinol for gout.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

Prolonged modified fasting, in a multimodal medical approach, may help patients with fibromyalgia improve pain and psychosomatic symptoms.

Patient-led urate monitoring supports adherence to urate-lowering therapy and helps attain target concentrations among individuals with gout.

In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

The presence of sinusitis is linked to a 40% heightened risk of a diagnosis of rheumatic disease, particularly in the 5 to 10 years before disease onset.

Patients with gout and negative DECTs for monosodium urate crystal deposition exhibited milder disease and a lower comorbidity burden.

Often considered a cause of symptom onset in musculoskeletal conditions, a new study found that weather factors do not appear to be a risk factor for pain.

The study performed the first genome-wide cross-trait analysis to investigate the shared genetic basis underlying hypothyroidism and rheumatoid arthritis.

A Mendelian randomization analysis provided new insights into the relationship between inflammatory cytokines and ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.

A review of 15 RCTS suggests that both electroacupuncture and conventional drugs demonstrate similar effectiveness in addressing pain for patients with acute gouty arthritis.

Mortality risks in gout have not improved in the United States in the past 3 decades, with a similar risk found among contemporary cases of gout in the United Kingdom.

A virtual screening combined with experimental verification identified the potential mechanism of fuzitang decoction in the treatment of Gouty Arthritis.

Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.